New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2013
05:31 EDTGWPHGW Pharmaceuticals announces Sativex regulatory approval in Switzerland
GW Pharmaceuticals announced that it has received regulatory approval for its prescription medicine Sativex in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW's European partner, Almirall S.A.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
09:00 EDTGWPHGW Pharmaceuticals falls 2.3%
GW Pharmaceuticals is down 2.3%, or $1.18, to $50.16

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use